Skip to content
NovaZone

Administering Pluripotent Cells During Pregnancy to Infants with Spina Bifida Improves Quality of Life, Trial Finds

A groundbreaking medical trial has found that delivering regenerative cells to developing infants diagnosed with spina bifida while undergoing fetal surgery could constitute a "major milestone" in treating birth defects.

Trial Details and Safety

The US-based trial focused on six fetuses with the 'open' form of spina bifida. Doctors administered regenerative cells sourced from the maternal placenta directly onto the baby's spinal cord as part of the surgical correction.

Significantly, the regenerative treatment demonstrated a favorable safety profile. The study team reported that the therapy did not induce cancerous growths, hinder surgical recovery, or impede the resolution of related neurological issues.

Encouraging Results

Post-birth MRI scans showed a complete reversal of Chiari malformation in each of the babies. This brain structure normalization is a key indicator for improved motor skills and quality of life.

"In the event it allows additional babies to achieve ambulation who otherwise would not, it may emerge as the new treatment paradigm," commented the principal investigator. "These findings are extremely promising and open the door to numerous possible novel therapies."

Future Implications and Hope

Experts not involved in the trial indicated that further confirmation of these apparent benefits could announce a "new era" in fetal surgery. The potential to improve neurological damage present before birth is viewed as a transformative goal.

Especially significant would be better management of urogenital and gastrointestinal outcomes, which are common challenges for individuals living with this disorder.

Future Directions

While this initial trial focused on a handful of cases, its safety demonstration and positive signals provide a strong foundation for larger, more comprehensive studies. The addition of cellular treatment with proven prenatal surgical methods holds considerable promise for improving the prognosis for infants diagnosed prenatally with this neural tube defect.

Written by

Francisco Dougherty

Elena Voss is a tech enthusiast and science communicator with a passion for exploring cutting-edge innovations.

NovaZone

Type to search articles.